JPRN-UMIN000005762Completed未知
The Study for Efficacy of Adalimumab Conbined Elemental Diet Therapy for Crohn's Disease - The Efficacy of Adalimumab
Kenji Watanabe0 sites40 target enrollmentStarted: June 13, 2011Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)The patient who has internal fistula 2)The patient who is planning to have an operation 3)The patient who is short bowel syndorome 4)The patient of contraindication for adalimumab or Elental 5)The case which is hard to get the patient's consent 6)The patient who was judged for unsuitable by responsibility doctor
Investigators
Similar Trials
Completed
Phase 4
Study of Combination Therapy of Adalimumab and an Immunomodulator for Crohn's Disease(Diamond study)s diseaseCrohn's diseaseJPRN-UMIN000005146Department of Internal Medicine, School of Medicine, Keio University200
Not yet recruiting
Phase 2
The effect of Adalimumab in the treatment of patients with chronic schizophreniaSchizophrenia.SchizophreniaIRCT20090117001556N126Tehran University of Medical Sciences50
Completed
Not Applicable
The Study for Efficacy and Safety of Adalimumab for Crohn's Disease with Loss of Response to InfliximabCrohn's Disease patient as following 1)or 2) 1)the patient who treated with IFX infusion of interval every 4-6 weeks. 2)the patient who could not keep to treat with IFX due to side effect or ineffectiveness.JPRN-UMIN000005761Kenji Watanabe50
Completed
Not Applicable
Effect of adacolumn and adalimumab combination therapy for the active stage Crohn's diseases diseaseCrohn's diseaseJPRN-UMIN000007047Yamaguchi University Graduate School of Medicine Department of Gastroenterology and Hepatology40
Recruiting
Phase 4
Effectiveness of adalimumab combined with adjuvant surgery versus adalimumab monotherapy in the treatment of hidradenitis suppurativa.NL-OMON50218Erasmus MC, Universitair Medisch Centrum Rotterdam62